EP1423081A4 - Composition comprenant des glycosaminoglycanes et des inhibiteurs d'hyaluronidase destinee au traitement d'articulations arthritiques - Google Patents

Composition comprenant des glycosaminoglycanes et des inhibiteurs d'hyaluronidase destinee au traitement d'articulations arthritiques

Info

Publication number
EP1423081A4
EP1423081A4 EP02739947A EP02739947A EP1423081A4 EP 1423081 A4 EP1423081 A4 EP 1423081A4 EP 02739947 A EP02739947 A EP 02739947A EP 02739947 A EP02739947 A EP 02739947A EP 1423081 A4 EP1423081 A4 EP 1423081A4
Authority
EP
European Patent Office
Prior art keywords
glycosaminogycans
treatment
composition
arthritic joints
hyaluronidase inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02739947A
Other languages
German (de)
English (en)
Other versions
EP1423081A2 (fr
Inventor
Jonathan Thompson
Anna Gosiewska
Susan Niemiec
Sridevi Dhanaraj
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DePuy International Ltd
Original Assignee
DePuy International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DePuy International Ltd filed Critical DePuy International Ltd
Publication of EP1423081A2 publication Critical patent/EP1423081A2/fr
Publication of EP1423081A4 publication Critical patent/EP1423081A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
EP02739947A 2001-06-25 2002-06-20 Composition comprenant des glycosaminoglycanes et des inhibiteurs d'hyaluronidase destinee au traitement d'articulations arthritiques Withdrawn EP1423081A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30073401P 2001-06-25 2001-06-25
US300734P 2001-06-25
US74102A 2002-06-06 2002-06-06
WOPCT/US74/00001 2002-06-06
PCT/US2002/019718 WO2003000191A2 (fr) 2001-06-25 2002-06-20 Composition comprenant des glycosaminoglycanes et des inhibiteurs d'hyaluronidase destinee au traitement d'articulations arthritiques

Publications (2)

Publication Number Publication Date
EP1423081A2 EP1423081A2 (fr) 2004-06-02
EP1423081A4 true EP1423081A4 (fr) 2005-05-25

Family

ID=26668090

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02739947A Withdrawn EP1423081A4 (fr) 2001-06-25 2002-06-20 Composition comprenant des glycosaminoglycanes et des inhibiteurs d'hyaluronidase destinee au traitement d'articulations arthritiques

Country Status (4)

Country Link
EP (1) EP1423081A4 (fr)
JP (1) JP2005521629A (fr)
CA (1) CA2451248A1 (fr)
WO (1) WO2003000191A2 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4703948B2 (ja) * 2003-05-20 2011-06-15 丸善製薬株式会社 抗アレルギー剤、抗老化剤及び抗老化用皮膚外用剤
WO2006020994A2 (fr) * 2004-08-13 2006-02-23 Angiotech International Ag Compositions et methodes utilisant de l'acide hyaluronique
AU2013270451B2 (en) * 2005-10-03 2016-05-12 Mark A. Pinsky Compositions and methods for improved skin care
JP2009537549A (ja) 2006-05-19 2009-10-29 トラスティーズ オブ ボストン ユニバーシティ 医療用潤滑剤およびゲルとしての新規の親水性ポリマー
WO2008139123A2 (fr) * 2007-05-11 2008-11-20 Galderma Research & Development Preparations pharmaceutiques ou cosmetiques pour application topique et/ou parenterale, leurs procedes de preparation, et leurs utilisations
WO2008139122A2 (fr) * 2007-05-11 2008-11-20 Galderma Research & Development Preparations pharmaceutiques ou cosmetiques pour application topique et/ou parenterale, leurs procedes de preparation, et leurs utilisations
US8394782B2 (en) 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having increased longevity
ITMI20072348A1 (it) 2007-12-17 2009-06-18 Medichem Srl Metodo per la rigenerazione cellulare di acido ialuronico e relativa composizione cosmetica
WO2009142892A1 (fr) * 2008-05-19 2009-11-26 The University Of North Carolina At Chapel Hill Procédés et compositions comprenant de nouveaux lipides cationiques
ITMI20090779A1 (it) * 2009-05-08 2010-11-08 Vitrupharm Srl Composizioni nutrizionali a base di resveratrolo cisteina o suoi derivati o metaboliti e astaxantina
US9216164B2 (en) 2009-07-23 2015-12-22 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated EPA and DHA
US9399047B2 (en) 2009-07-23 2016-07-26 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using phospholipids and roe extract
US8481072B2 (en) 2009-07-23 2013-07-09 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain
US9238043B2 (en) 2009-07-23 2016-01-19 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using algae based oils
US8557275B2 (en) 2009-07-23 2013-10-15 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated EPA and DHA
US9913810B2 (en) 2009-07-23 2018-03-13 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using phospholipids and astaxanthin
US9402857B2 (en) 2009-07-23 2016-08-02 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using low molecular weight hyaluronic acid and astaxanthin
US8637569B2 (en) 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
MX338211B (es) * 2009-10-22 2016-03-30 Api Genesis Llc Metodos para hacer y utilizar composiciones que comprenden flavonoides.
WO2011160146A1 (fr) * 2010-06-23 2011-12-29 Croma-Pharma Gesellschaft M.B.H. Préparation pharmaceutique contenant du dextrane et de l'hyaluronate de sodium pour le traitement de troubles articulaires
US8716204B2 (en) 2010-07-27 2014-05-06 Zimmer, Inc. Synthetic synovial fluid compositions and methods for making the same
ITRM20100614A1 (it) * 2010-11-24 2012-05-25 D M G Italia S R L Preparazioni farmaceutiche dell acido 18 beta glicirretico e/o di suoi derivati per infiltrazioni intrarticolari per il trattamento delle artropatie infiammatorie
FR2991876B1 (fr) 2012-06-13 2014-11-21 Vivacy Lab Composition, en milieu aqueux, comprenant au moins un acide hyaluronique et au moins un sel hydrosoluble de sucrose octasulfate
AU2016307289B2 (en) * 2015-08-13 2023-01-05 Simon Troy Humphrys Composition for the treatment of joint conditions
DE102016208567A1 (de) * 2016-05-19 2017-11-23 Heraeus Medical Gmbh Polymerlösung zur Viscosupplementation
WO2019038763A1 (fr) 2017-08-22 2019-02-28 Moebius Medical Ltd. Formulation liposomale pour lubrification d'articulation
CN109758607B (zh) * 2019-03-08 2021-07-27 宁夏妙朗生物科技有限公司 抵抗透明质酸酶水解的交联透明质酸凝胶

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990012561A1 (fr) * 1989-04-20 1990-11-01 Bukh Meditec A/S (Niels Bukh A/S) Preparation cosmetique
WO2000074662A2 (fr) * 1999-06-07 2000-12-14 University Of Sheffield Traitement de l'arthrite

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2374910A1 (fr) * 1976-10-23 1978-07-21 Choay Sa Preparation a base d'heparine, comprenant des liposomes, procede pour l'obtenir et medicaments contenant de telles preparations
US4743596A (en) * 1987-06-16 1988-05-10 Lapin Alfred R Anti-arthritic preparation
AU760735B2 (en) * 1998-09-28 2003-05-22 Merck & Co., Inc. A method for treating inflammatory diseases by administering a thrombin inhibitor
US6136795A (en) * 1998-11-18 2000-10-24 Omni Nutraceuticals, Inc Dietary regimen of nutritional supplements for relief of symptoms of arthritis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990012561A1 (fr) * 1989-04-20 1990-11-01 Bukh Meditec A/S (Niels Bukh A/S) Preparation cosmetique
WO2000074662A2 (fr) * 1999-06-07 2000-12-14 University Of Sheffield Traitement de l'arthrite

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KUPPUSAMY U R ET AL: "STRUCTURE-ACTIVITY STUDIES OF FLAVONOIDS AS INHIBITORS OF HYALURONIDASE", BIOCHEMICAL PHARMACOLOGY, vol. 40, no. 2, 1990, pages 397 - 401, XP002322723, ISSN: 0006-2952 *
TORSTEINSDOTTIR I ET AL: "Production and elimination of hyaluronan in rheumatoid arthritis patients: estimation with a loading test", SEMINARS IN ARTHRITIS AND RHEUMATISM, XX, XX, vol. 28, no. 4, February 1999 (1999-02-01), pages 268 - 279, XP004680850, ISSN: 0049-0172 *

Also Published As

Publication number Publication date
EP1423081A2 (fr) 2004-06-02
JP2005521629A (ja) 2005-07-21
CA2451248A1 (fr) 2003-01-03
WO2003000191A2 (fr) 2003-01-03
WO2003000191A3 (fr) 2004-03-11

Similar Documents

Publication Publication Date Title
EP1423081A4 (fr) Composition comprenant des glycosaminoglycanes et des inhibiteurs d'hyaluronidase destinee au traitement d'articulations arthritiques
EP1390014A4 (fr) Composition et procedes de traitement d'hyperplasie
HK1094909A1 (en) Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis il-18
EP1416961A4 (fr) Composition et procede pour le traitement d'une maladie
EP1572890A4 (fr) Slc7s utilises en tant que modificateurs de la voie p53 et procedes d'utilisation correspondants
PL375052A1 (en) Pharmaceutical pig and method of use
AU2002364364A8 (en) Method of treating apoptosis and compositions thereof
HK1152474A1 (en) Methods and compositions for the prevention and treatment of sepsis
EP1406571A4 (fr) Encapsulation liposomale de glycosaminoglycanes pour le traitement d'articulations arthrosees
EP1448218A4 (fr) Inhibiteurs de la beta-secretase et leurs procede d'utilisation
EP1421384A4 (fr) Hprp4 en tant que modificateurs de la voie de passage p53 leurs et methodes d'utilisation
AU2001274181A1 (en) Composition and method for biocide treatment of surfaces
EP1492902A4 (fr) Composition et procede de traitement de surfaces metalliques
AU2002364171A8 (en) Materials and methods for the treatment or prevention of obesity
AU2002337913A1 (en) Glycosulfopeptide inhibitors and methods of use thereof
HK1062810A1 (en) Use of il-18 inhibitors for the manufacture of medicaments for treatment and/or prevention of heartdisease
PL368035A1 (en) Compositions and methods for the treatment of cancer
GB0504457D0 (en) Treatment of pipes
GB0111347D0 (en) Pipes and manufacture of such pipes
AU2002303552A8 (en) Methods and compositions for prevention of angioproliferation
GB0114572D0 (en) A method for the treatment of textile surfaces and compositions for use therein
EP1414427A4 (fr) Compositions a base de kavalactone et leurs procedes d'utilisation
EP1557169A4 (fr) Agent therapeutique et/ou prophylactique pour la dyschezie
EP1385510A4 (fr) Composition de prodigiosine pour le traitement de l'arthrite rhumatismale
AU3964100A (en) Corrosive preventive composition and method of using the same

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040120

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 9/127 B

Ipc: 7A 61K 31/715 B

Ipc: 7A 61K 31/725 B

Ipc: 7A 61K 31/72 A

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DEPUY INTERNATIONAL LIMITED

A4 Supplementary search report drawn up and despatched

Effective date: 20050412

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61P 29/00 B

Ipc: 7A 61K 31/4152 B

Ipc: 7A 61K 31/352 B

Ipc: 7A 61K 33/24 B

Ipc: 7A 61K 31/728 B

Ipc: 7A 61K 31/727 B

Ipc: 7A 61K 31/726 B

Ipc: 7A 61K 9/127 B

Ipc: 7A 61K 31/715 A

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060904